Resum
Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer and there is
growing evidence of HPV being a relevant factor in other anogenital cancers (anus, vulva, vagina and
penis) and head and neck cancers. HPV types 16 and 18 are responsible for about 70% of all cervical
cancer cases worldwide. HPV vaccines that prevent against HPV 16 and 18 infection are now available
and have the potential to reduce the incidence of cervical and other anogenital cancers.
This report provides key information for Spain on cervical cancer, other anogenital cancers and head
and neck cancers, HPV-related statistics, factors contributing to cervical cancer, cervical cancer screening
practices, HPV vaccine introduction, and other relevant immunization indicators. The report is
intended to strengthen the guidance for health policy implementation of primary and secondary cervical
cancer prevention strategies in the country.
Spain has a population of 20.24 million women aged 15 years and older who are at risk of developing
cervical cancer. Current estimates indicate that every year 2511 women are diagnosed with cervical
cancer and 848 die from the disease.Cervical cancer in Spain ranks as the 10th most frequent cancer
among women and the 2nd most frequent cancer among women between 15 and 44 years of age. Based
on Spain studies performing HPV detection tests in cervical samples, about 10.7% of women in the general
population are estimated to harbour cervical HPV infection at a given time, and 57.4% of invasive
cervical cancers are attributed to HPVs 16 or 18.
Autoria:
BRUNI, Laia;
BROTONS, M.;
ALBERO, Ginesa;
BARRIONUEVO ROSAS, Leslie;
SERRANO, Beatriz;
COSANO, R.;
MUÑOZ, Jesús;
BOSCH JOSÉ, Francesc Xavier;
SANJOSÉ, Sílvia de;
CASTELLSAGUÉ PIQUÉ, Xavier
Autoria institucional:
ICO (Institut Català d'Oncologia) (España)